Prevalence of, evolution of, and risk factors for fat atrophy and fat deposition in a cohort of HIV-infected men and women. - Wikidata - wikimedia - TriplyDB

Prevalence of, evolution of, and risk factors for fat atrophy and fat deposition in a cohort of HIV-infected men and women.

Prevalence of, evolution of, and risk factors for fat atrophy and fat deposition in a cohort of HIV-infected men and women.

http://www.wikidata.org/entity/Q46503398

about

HIV-associated adipose redistribution syndrome (HARS): etiology and pathophysiological mechanisms The role of protease inhibitors in the pathogenesis of HIV-associated lipodystrophy: cellular mechanisms and clinical implications Narrative review: the role of leptin in human physiology: emerging clinical applications Leptin's role in lipodystrophic and nonlipodystrophic insulin-resistant and diabetic individuals HIV infection and the risk of acute myocardial infarction.Nutrition issues in chronic drug users living with HIV infection.Adherence to the Mediterranean diet is associated with a lower risk of body-shape changes in Croatian patients treated with combination antiretroviral therapy.HIV-associated lipodystrophy: a review from a Brazilian perspective Leptin in human physiology and therapeutics Leptin replacement improves postprandial glycemia and insulin sensitivity in human immunodeficiency virus-infected lipoatrophic men treated with pioglitazone: a pilot study.Anthropometric differences between HIV-infected individuals prior to antiretroviral treatment and the general population from 1998-2007: the AIDS Clinical Trials Group Longitudinal Linked Randomized Trials (ALLRT) cohort and NHANES.Tubal factor infertility and perinatal risk after assisted reproductive technology.Prevalence of and Risk Factors for Lipoatrophy in Patients with HIV Infection in Nigeria The effects of exercise training on quality of life in HAART-treated HIV-positive Rwandan subjects with body fat redistribution.Leptin in human physiology and pathophysiology.New and emerging agents in the management of lipodystrophy in HIV-infected patients.Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy Body fat distribution in perinatally HIV-infected and HIV-exposed but uninfected children in the era of highly active antiretroviral therapy: outcomes from the Pediatric HIV/AIDS Cohort Study.Gender-specific effects of HIV protease inhibitors on body mass in mice.Viral mechanisms of adipose dysfunction: lessons from HIV-1 Vpr A Randomized Comparison of Anthropomorphic Changes With Preferred and Alternative Efavirenz-Based Antiretroviral Regimens in Diverse Multinational Settings Body composition and metabolic changes in HIV-infected patients Management of the metabolic effects of HIV and HIV drugs.A randomized trial of Raltegravir replacement for protease inhibitor or non-nucleoside reverse transcriptase inhibitor in HIV-infected women with lipohypertrophy.Body Composition Changes After Initiation of Raltegravir or Protease Inhibitors: ACTG A5260s Approach to the human immunodeficiency virus-infected patient with lipodystrophy Accelerated Aging in HIV Patients.Body-fat abnormalities in patients with HIV: progress and challenges.Mitochondrial DNA haplogroups influence lipoatrophy after highly active antiretroviral therapy Evolution and predictors of change in total bone mineral density over time in HIV-infected men and women in the nutrition for healthy living study Exercise training reduces central adiposity and improves metabolic indices in HAART-treated HIV-positive subjects in Rwanda: a randomized controlled trial From old to new nucleoside reverse transcriptase inhibitors: changes in body fat composition, metabolic parameters and mitochondrial toxicity after the switch from thymidine analogs to tenofovir or abacavir.Management of fat accumulation in patients with HIV infection.Nutrition and the HIV-associated lipodystrophy syndrome.The Facial Appearance Inventory: Development and Preliminary Evidence for Reliability and Validity in People with HIV and Lipoatrophy.Visceral fat is associated with brain structure independent of human immunodeficiency virus infection status.Clinical and color Doppler ultrasound evaluation of polyacrylamide injection in HIV patients with severe facial lipoatrophy secondary to antiretroviral therapy.Body composition in HIV-infected patients receiving highly active antiretroviral therapy.Contribution of genetic background and antiretroviral therapy to body fat changes in antiretroviral-naive HIV-infected adults.Nutrition issues in the HIV-infected injection drug user: findings from the nutrition for healthy living cohort.

P2860

Q21245028-EB8A8C54-ACA6-4D65-90A4-5188C3C511F0 Q24598812-6A9A1395-24F2-4FEF-9B79-D8753D338D5A Q24634811-19949071-B69A-4CBD-A81D-64058780E79E Q26859118-E32DF2DA-EA2B-4345-BF39-7BB1F3F1E658 Q27347231-8CF428D3-3BB2-4292-9A2D-85601470DC39 Q33553170-7D28AC33-7620-4BB4-8C44-7A220D50176D Q33752752-844EF965-D03D-4B4E-B71D-42F33272C279 Q33939681-495307EB-3CDB-4969-9EF2-45EC559D923B Q34047024-45478069-E47A-4BA8-8590-DE921B086A0D Q34672147-21C535C7-F4A3-403A-8E09-E19E6D1BA6DE Q34766373-DA2A9979-2F1D-4838-9A6F-5D4C01A3F401 Q34938041-95A9D193-18D6-4CAD-9DEF-BD0086D60F98 Q35187774-CDE804B2-9802-4E07-A5CA-14467CCCF721 Q35196974-D99B0FFF-076E-44B6-8ECD-D099ED8D17CB Q35321788-6E079E27-D70A-4A2D-94B1-A3D5B95B8496 Q35557229-7BB1470F-CAB6-4551-AFA0-D3EE3DE26761 Q35557342-D9856CA8-5156-427A-A695-19F9FDDDE3A1 Q35656425-90AB4771-0A3A-4BBE-9750-D7E4D678BFD6 Q35793960-D9A8A869-6524-4228-8388-7DC0C9AAB87A Q35834850-1B2AE61D-FA28-4319-99DE-034CE491B1F2 Q35881469-C21D5502-6BDD-462E-913F-803A3006BCAE Q35949965-5C36351D-24C3-4991-B3C5-14BAB6184513 Q36021411-0C4270C3-295F-44B4-BA38-AE28442C6EB2 Q36184633-5BD8CC86-D9B0-472D-A1C7-65A2EEF7AFDC Q36676379-BB492CA9-ABA0-4886-850E-93ADA08D19DB Q36834945-B506B3AA-1E82-449F-9480-25251EC13A15 Q36919221-1A1F5842-72E7-4C01-B4EC-2C03C8566F40 Q37341305-C3216A76-5025-4910-945E-2034E0D9D592 Q37344333-90B99485-C915-4942-BA9F-EC6E487FBEE9 Q37596221-6DDAC223-A5DD-441C-85DB-2F0C1F426F90 Q37606654-9C54F827-0443-407D-89A0-86C9452FA5CA Q37828539-600E9E9E-8557-47A3-84F2-B5DA1E86266B Q37899071-43DB693A-8E54-4727-A12F-15C821D8313E Q38061798-3AA833AF-94DB-449D-80CE-7DF979F69EFF Q39956469-E6C9A61C-C423-4505-9B8A-034A6183450A Q40407612-42D8B49B-DA73-4084-B91E-071E2EFB8A15 Q40475214-31D38E7B-28B9-4CA1-8E96-D515954AEDE3 Q40511639-E0CF3012-0AAB-45C4-B2DD-40AD991C9D35 Q41756147-C3709C04-7683-42E6-BA9A-052269DA1093 Q44156088-EC3A57AB-E0B0-4E09-84ED-F4750966683E

P2860

Prevalence of, evolution of, and risk factors for fat atrophy and fat deposition in a cohort of HIV-infected men and women.

http://www.wikidata.org/entity/Q46503398

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh-hant

name

Prevalence of, evolution of, a ...... of HIV-infected men and women.

@en

Prevalence of, evolution of, a ...... of HIV-infected men and women.

@nl

type

label

Prevalence of, evolution of, a ...... of HIV-infected men and women.

@en

Prevalence of, evolution of, a ...... of HIV-infected men and women.

@nl

prefLabel

Prevalence of, evolution of, a ...... of HIV-infected men and women.

@en

Prevalence of, evolution of, a ...... of HIV-infected men and women.

@nl

P1433

Q46503398-C45EE77C-3B0D-4C7D-BD7B-8C07A9023BEF

P1476

Q46503398-B1B5FEA7-4A7C-4F0E-88AD-28DC3A179F20

P2093

Q46503398-5E8853BE-7E5F-4F64-A5A9-F95897B40AFD

Q46503398-63DD8412-E025-480C-8146-1D8412C7E7B8

Q46503398-76F0666E-3092-4FDE-9020-E49C3173AFE3

Q46503398-DB384022-C143-41D3-962D-D06D01642101

Q46503398-FDE6D1EC-172D-41A9-BB2F-94BC2E8E0943

P2860

Q46503398-127BFC83-14A0-49BA-982E-0D79DCD9D09F

Q46503398-1761A0F3-20BA-4573-ACFA-493CAFB4AC57

Q46503398-21C893C0-6740-4B28-82EC-6576CFC47A66

Q46503398-276EE844-EDC3-4557-A0BD-9C8F6E6AE471

Q46503398-3D9FBF48-CAF0-4C7E-810B-87E3506E3FE9

Q46503398-41A98987-BF06-436B-9C67-64BF02EEF79C

Q46503398-45A9EF72-F816-4888-A5E6-176F9731C26A

Q46503398-4B17BDFE-B0F2-4FF7-9248-1CBC4C3B1CC7

Q46503398-4B91C270-2F6B-401E-A140-3DF0BCE34E9E

Q46503398-4C968B0C-D26E-4442-A65A-D033478531C7

P304

Q46503398-5A8B88C0-0BCF-4472-90D3-3B808F9471D0

P31

Q46503398-C7C8733B-1EE1-4CF1-9EC1-1AFDF8D77E11

P356

Q46503398-CC72C0E2-EB45-4ADE-8B3D-F3F92ABC9C6F

P407

Q46503398-763EB264-D407-495D-A897-2E3448461613

P433

Q46503398-E3D8BC8D-900A-4F7D-BD79-08BA93AFDDE5

P478

Q46503398-B34B0F19-71D9-4A8C-B00A-B7A82D1BF9DF

P50

Q46503398-D5D48538-FECF-4740-9812-68805DF30DB2

P577

Q46503398-559504C0-B3A8-4F3E-8C63-78D9A813908A

P5875

Q46503398-02D31F97-DC53-47B4-B2EF-F74C2427CAF9

P698

Q46503398-513662A6-2111-4BA5-B42E-347AA2A19A1E

P356

P1433

Clinical Infectious Diseases

P1476

Prevalence of, evolution of, a ...... of HIV-infected men and women.

@en

P2093

Christine Wanke

http://www.w3.org/2001/XMLSchema#string

Denise L Jacobson

http://www.w3.org/2001/XMLSchema#string

Sally Skinner

http://www.w3.org/2001/XMLSchema#string

Sherwood Gorbach

http://www.w3.org/2001/XMLSchema#string

Tamsin Knox

http://www.w3.org/2001/XMLSchema#string

P2860

A modified poisson regression approach to prospective studies with binary data

Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database.

Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study.

Waist circumference as a measure for indicating need for weight management.

Incidence of adipose tissue alterations in first-line antiretroviral therapy: the LipoICoNa Study.

Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy.

Elevated resting energy expenditure among HIV-seropositive persons receiving highly active antiretroviral therapy.

Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy.

Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection.

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors.

P304

1837-1845

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1086/430379

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

40

http://www.w3.org/2001/XMLSchema#string

P50

Donna Spiegelman

P577

2005-05-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7832838

http://www.w3.org/2001/XMLSchema#string

P698

15909274

http://www.w3.org/2001/XMLSchema#string